Article
Impact of Lipoprotein (a) on Residual Cardiovascular Risk after an Acute Coronary Syndrome
2026-02-05
Abstract excerpt
Reducing residual cardiovascular risk following an acute coronary syndrome (ACS) remains a major unmet clinical need. Despite substantial advances in lipid-lowering therapies, the risk of recurrent major adverse cardiovascular events (MACE) after ACS remains high, with an estimated incidence of approximately 33.4% at 5 years. Residual cardiovascular risk is driven by multiple mechanisms, including persistent infla...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- f8b3260d-910f-5893-a1bc-64fc330d7b5e
- DOI
- 10.20944/preprints202602.0291.v1
